摘要：Xin H, Harris LA, Aban IB, Cutter G. Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in th

参考文献：

[1]Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015 Oct;14(10):1023-36.

[2]Xin H, Harris LA, Aban IB, Cutter G. Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample. J Clin Neurol. 2019 Jul;15(3):376-385.

[3]Utsugisawa K Nagane Y Uzawa A Murai H Imai T Suzuki S. Health-related quality of life and treatment strategies in myasthenia gravis. Clin Exp Neuroimmunol. 2020; 11: 209-217

[4]Bril V, Benatar M, Andersen H; MG0002 Investigators. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. Neurology. 2021 Feb 9;96(6):e853-e865.

[5]Bril V, Drużdż A, Grosskreutz J; MG0003 study team. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023 May;22(5):383-394.

[6]Habib AA, et al. Efficacy and Safety of Rozanolixizumab Treatment Cycles in Patients With Generalised Myasthenia Gravis: Final Pooled Analysis of Phase 3 Studies. MGFA 2025. Poster 71.

[7]Vu T, et al. Responder and Minimal Symptom Expression Rates With Rozanolixizumab in Generalised Myasthenia Gravis: Final Pooled Analysis of Phase 3 Studies. MGFA 2025. Poster 206.

[8]Zabeen K, et al. Effect of rozanolixizumab on ocular symptoms in patients with generalized myasthenia gravis: A post hoc item-level analysis of myasthenia gravis-speciffc outcomes in MycarinG. AAN 2025. Poster P1-11-006.

[9]Wallace T, et al. Effect of rozanolixizumab on bulbar and respiratory symptoms in patients with generalized myasthenia gravis: A post hoc item-level analysis of MycarinG. AAN 2025.

[10]Carlo Antozzi, et al. Patient preferences and experience with self-administration of rozanolixizumab in generalised myasthenia gravis: The MG0020 study. MGFA International 2025. Poster 4.

[11]Vera Bril, et al. Self-administration of rozanolixizumab in patients with generalized myasthenia gravis: The MG0020 study. AAN 2025. Poster P1-11-018.

[CN-RZ-2500050 有效期截止：2027年5月] 本内容仅供医疗卫生专业人士阅读，所含信息不应代替医疗卫生专业人士提供的医疗建议，也不建议医疗卫生专业人士超出说明书范围使用所涉及的药物。

声明：本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

来源：医脉通神经科